期刊论文详细信息
BMC Cell Biology
Mitochondrial localization of the OAS1 p46 isoform associated with a common single nucleotide polymorphism
Pia Møller Martensen2  Just Justesen2  Erik Ilsø Christensen1  Jesper Buchhave Poulsen2  Mariann Fagernæs Hansen2  Jytte Pahus2  Karina Hansen Kjær2 
[1] Department of Biomedicine, Aarhus University, Wilhelm Meyers Allé 3, 8000 Aarhus C, Denmark;Department of Molecular Biology and Genetics, Aarhus University, C.F. Møllers Allé 3, 8000 Århus C, Denmark
关键词: Diabetes;    Mitochondria;    Single Nucleotide Polymorphism (SNP);    2'-5' Oligoadenylate Synthetase (OAS);   
Others  :  1088723
DOI  :  10.1186/1471-2121-15-33
 received in 2014-04-16, accepted in 2014-08-29,  发布年份 2014
PDF
【 摘 要 】

Background

The expression of 2′-5′-Oligoadenylate synthetases (OASs) is induced by type 1 Interferons (IFNs) in response to viral infection. The OAS proteins have a unique ability to produce 2′-5′ Oligoadenylates, which bind and activate the ribonuclease RNase L. The RNase L degrades cellular RNAs which in turn inhibits protein translation and induces apoptosis. Several single nucleotide polymorphisms (SNPs) in the OAS1 gene have been associated with disease. We have investigated the functional effect of two common SNPs in the OAS1 gene. The SNP rs10774671 affects splicing to one of the exons in the OAS1 gene giving rise to differential expression of the OAS1 isoforms, and the SNP rs1131454 (former rs3741981) resides in exon 3 giving rise to OAS1 isoforms with either a Glycine or a Serine at position 162 in the core OAS unit.

Results

We have used three human cell lines with different genotypes in the OAS1 SNP rs10774671, HeLa cells with the AA genotype, HT1080 cells with AG, and Daudi cells with GG. The main OAS1 isoform expressed in Daudi and HT1080 cells was p46, and the main OAS1 isoform expressed in HeLa cells was p42. In addition, low levels of the OAS1 p52 mRNA was detected in HeLa cells and p48 mRNA in Daudi cells, and trace amounts of p44a mRNA were detected in the three cell lines treated with type 1 interferon. We show that the OAS1 p46 isoform was localized in the mitochondria in Daudi cells, whereas the OAS1 isoforms in HeLa cells were primarily localized in cytoplasmic vacuoles/lysosomes. By using recombinantly expressed OAS1 mutant proteins, we found that the OAS1 SNP rs1131454 (former rs3741981) did not affect the enzymatic OAS1 activity.

Conclusions

The SNP rs10774671 determines differential expression of the OAS1 isoforms. In Daudi and HT1080 cells the p46 isoform is the most abundantly expressed isoform associated with the G allele, whereas in HeLa cells the most abundantly expressed isoform is p42 associated with the A allele. The SNP rs1131454 (former rs3741981) does not interfere with OAS1 enzyme activity. The OAS1 p46 isoform localizes to the mitochondria, therefore a full 2-5A system can now be found in the mitochondria.

【 授权许可】

   
2014 Kjær et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150122011632166.pdf 1965KB PDF download
Figure 7. 137KB Image download
Figure 6. 38KB Image download
Figure 5. 143KB Image download
Figure 4. 19KB Image download
Figure 3. 70KB Image download
20150101011608802.pdf 203KB PDF download
Figure 1. 60KB Image download
【 图 表 】

Figure 1.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】
  • [1]Sadler AJ, Williams BRG: Interferon-inducible antiviral effectors. Nat Rev Immunol 2008, 8:559-568.
  • [2]Randall RE, Goodbourne S: Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89:1-47.
  • [3]Hovanessian AG, Justesen J: The human 2′-5′oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′ instead of 3′-5′ phosphodiester bond formation. Biochimie 2007, 89(6–7):779-788.
  • [4]Justesen J, Hartmann R, Kjeldgaard NO: Gene structure and function of the 2′-5′-oligoadenylate synthetase family. Cell Mol Life Sci 2000, 57(11):1593-1612.
  • [5]Marie I, Hovanessian AG: The 69-kDa 2-5A synthetase is composed of two homologous and adjacent functional domains. J Biol Chem 1992, 267(14):9933-9939.
  • [6]Chebath J, Benech P, Hovanessian A, Galabru J, Revel M: Four different forms of interferon-induced 2′,5′-oligo(A) synthetase identified by immunoblotting in human cells. J Biol Chem 1987, 262(8):3852-3857.
  • [7]Hovanessian AG, Laurent AG, Chebath J, Galabru J, Robert N, Svab J: Identification of 69-kd and 100-kd forms of 2-5A synthetase in interferon-treated human cells by specific monoclonal antibodies. EMBO J 1987, 6(5):1273-1280.
  • [8]Ghosh A, Sakar SN, Rowe TM, Sen GC: A specific isozyme of 2′-5′ Oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J Biol Chem 2001, 276:25447-25455.
  • [9]Bonnevie-Nielsen V, Field LL, Lu S, Zheng DJ, Li M, Martensen PM, Nielsen TB, Beck-Nielsen H, Lau YL, Pociot F: Variation in antiviral 2′,5′-oligoadenylate synthetase (2′5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 2005, 76(4):623-633.
  • [10]Noguchi S, Hamano E, Matsushita I, Hijikata M, Ito H, Nagase T, Keicho N: Differential effects of a common splice site polymorphism on the generation of OAS1 variants in human bronchial epithelial cells. Hum Immunol 2013, 74:395-401.
  • [11]Besse S, Rebouillat D, Marie I, Puvion-Dutilleul F, Hovanessian AG: Ultrastructural localization of interferon-inducible double-stranded RNA-activated enzymes in human cells. Exp Cell Res 1998, 239(2):379-392.
  • [12]Rebouillat D, Hovanain A, Marie I, Hovanessian AG: The 100-kDa 2′,5′-oligoadenylate synthetase catalysing preferentially the synthesis of dimeric pppA2′p5′A molecules is composed of three homologous domains. J Biol Chem 1999, 274:1557-1565.
  • [13]Benech P, Mory Y, Revel M, Chebath J: Structure of two forms of the interferon-induced (2′-5′) oligo A synthetase of human cells based on cDNAs and gene sequences. EMBO J 1985, 4(9):2249-2256.
  • [14]Field LL, Bonnevie-Nielsen V, Pociot F, Lu S, Nielsen TB, Beck-Nielsen H: OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes 2005, 54:1588-1591.
  • [15]Tessier MC, Qu HQ, Frechette R, Bacot F, Grabs R, Taback SP, Lawson ML, Kirsch SE, Hudson TJ, Polychronakos C: Type 1 diabetes and the OAS gene cluster: association with splicing polymorphism or haplotype? J Med Genet 2006, 43(2):129-132.
  • [16]Smyth DJ, Cooper JD, Lowe CE, Nutland S, Walker NM, Clayton DG, Todd JA: No evidence for association of OAS1 with Type 1 diabetes in unaffected siblings or Type 1 diabetic cases. Diabetes 2006, 55:1525-1528.
  • [17]Qu HQ, Polychronakos C: Reassessment of the type I diabetes association of the OAS1 locus. Genes Immun 2009, 10(Suppl 1):S69-S73.
  • [18]Fedetz M, Matesanz F, Caro-Maldonado A, Fernandez O, Tamayo JA, Guerrero M, Delgado C, Lopez-Guerrero JA, Alcina A: OAS1 gene haplotype confers susceptibility to multiple sclerosis. Tissue Antigens 2006, 68(5):446-449.
  • [19]O’Brien M, Lonergan R, Costelloe L, O’Rourke K, Fletcher JI, Kinsella K, Sweeney C, Antonelli G, Mills KH, O’Farrelly C, Hutchinson M, Tubridy N: OAS1. A multiple sclerosis susceptibility gene that influences disease severity. Neurology 2010, 75:411-418.
  • [20]Cagliani R, Fumagalli M, Guerini FR, Riva S, Galimberti D, Comi GP, Agliardi C, Scarpini E, Pozzoli U, Forni D, Caputo D, Asselta R, Biasin M, Paraboschi EM, Bresolin N, Clerici M, Sironi M: Identification of a new susceptibility variant for multiple sclerosis in OAS1 by population genetics analysis. Hum Genet 2012, 131:87-97.
  • [21]Haralambieva IH, Ovsyannikova IG, Umlauf BJ, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA: Genetic polymorphims in host antiviral genes: Associations with humoral and cellular immunity to measels vaccine. Vaccine 2011, 29:8988-8997.
  • [22]Haralambieva IH, Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA: 2′-5′-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine. Hum Immunol 2010, 71(4):383-391.
  • [23]Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, Follmann D, Stramer SL, Margolis LB, Murphy PM: Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog 2009, 5(2):e1000321.
  • [24]Bigham AW, Buckingham KJ, Husain S, Emond MJ, Bofferding KM, Gildersleeve H, Rutherford A, Astakhova NM, Perelygin AA, Busch MP, Murray KO, Sejvar JJ, Green S, Kriesel J, Brinton MA, Bamshad M: Host genetic risk factors for West Nile Virus infection and disease progression. PLoS One 2011, 6:e2475.
  • [25]Awady MKE, Anany MA, Esmat G, Zayed N, Tabll AA, Helmy A, Zayady AR, Abdalla MS, Sharada HM, Raziky ME, Akel WE, Abdalla S, Din NGBE: Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. J Gastroenterol Hepatol 2011, 26:843-850.
  • [26]Kwon Y-C, Kang J-I, Hwang SB, Ahn B-Y: The ribonuclease L-dependent antiviroal roles of human 2′,5′-oligoadenylate synthetase family members against hepatitis C virus. FEBS Lett 2013, 587:156-164.
  • [27]Lin R-J, Yu H-P, Chang B-L, Tang W-C, Liao C-L, Lin Y-L: Distinct antiviral roles for human 2′,5′-oligoadenylate synthetase family members against dengue virus infection. J Immunol 2009, 183:8035-8043.
  • [28]Witt PL, Marié I, Robert N, Irizarry A, Borden EC, Hovanessian AG: Isoforms p69 and p100 of 2′,5′-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro. J Interferon Res 1993, 13:17-23.
  • [29]Poulsen JB, Andersen KR, Kjaer KH, Durand F, Faou P, Vestergaard AL, Talbo GH, Hoogenraad N, Brodersen DE, Justesen J, Martensen PM: Human 2′-phosphodiesterase localizes to the mitochondrial matrix with a putative function in mitochondrial RNA turnover. Nucleic Acids Res 2011, 39(9):3754-3770.
  • [30]Benech P, Merlin G, Revel M, Chebath J: 3′ end structure of the human (2′-5′) oligo A synthetase gene: prediction of two distinct proteins with cell type-specific expression. Nucl Acid Res 1985, 13(4):1267-1281.
  • [31]Khanna KK, An SJ, Wu JM, Landolfo S, Hovanessian AG: Absence of the 40-kDa form of (2′-5′)oligoadenylate synthetase and its corresponding mRNA from skin fibroblasts derived from Alzheimer disease patients. Proc Natl Acad Sci U S A 1991, 88(13):5852-5856.
  • [32]Tait SWG, Green DR: Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010, 11:621-632.
  • [33]Kjaer KH, Poulsen JB, Reintamm T, Saby E, Martensen PM, Kelve M, Justesen J: Evolution of the 2′-5′-oligoadenylate synthetase family in eukaryotes and bacteria. J Mol Evol 2009, 69(6):612-624.
  • [34]Lane KT, Beese LS: Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res 2006, 47(4):681-699.
  • [35]Le Roy F, Bisbal C, Silhol M, Martinand C, Lebleu B, Salehzada T: The 2-5A/RNase L/RNase L inhibitor (RLI) [correction of (RNI)] pathway regulates mitochondrial mRNAs stability in interferon alpha-treated H9 cells. J Biol Chem 2001, 276(51):48473-48482.
  • [36]Floyd-Smith G, Yoshie O, Lengyel P: Interferon action. Covalent linkage of (2′-5′)pppApApA(32P)pCp to (2′-5′) (A)n-dependent ribonucleases in cell extracts by ultraviolet irradiation. J Biol Chem 1982, 257(15):8584-8587.
  • [37]Bayard BA, Gabrion JB: 2′,5′-Oligoadenylate-dependent RNAse located in nuclei: biochemical characterization and subcellular distribution of the nuclease in human and murine cells. Biochem J 1993, 296(Pt 1):155-160.
  • [38]Rorbach J, Nicholls TJ, Minczuk M: PDE12 removes mitochondrial RNA poly(A) tails and controls translation in human mitochondria. Nucleic Acids Res 2011, 39(17):7750-7763.
  • [39]Le Roy F, Silhol M, Salehzada T, Bisbal C: Regulation of mitochondrial mRNA stability by RNase L is translation-dependent and controls IFNalpha-induced apoptosis. Cell Death Differ 2007, 14(8):1406-1413.
  • [40]Reed SE, Staley EM, Mayginnes JP, Pinel DJ, Tullis GE: Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombiant adeno-associated virus vectors. J Virol Methods 2006, 138:85-98.
  • [41]Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29(9):e45.
  • [42]Saby E, Poulsen JB, Justesen J, Kelve M, Uriz MJ: 2′-phosphodiesterase and 2′,5′-oligoadenylate synthetase activities in the lowest metazoans, sponge [porifera]. Biochimie 2009, 91:1531-1534.
  • [43]Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012, 9:671-675.
  文献评价指标  
  下载次数:63次 浏览次数:28次